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Psoriasis is a common inflammatory disorder of the skin and other organs. We have determined that mutations in CARD14, encoding
a nuclear factor of kappa light chain enhancer in B cells (NF-kB) activator within skin epidermis, account for PSORS2. Here, we describe
fifteen additional raremissense variants inCARD14, their distribution in seven psoriasis cohorts (>6,000 cases and>4,000 controls), and
their effects on NF-kB activation and the transcriptome of keratinocytes. There were more CARD14 rare variants in cases than in controls
(burden test p value ¼ 0.0015). Some variants were only seen in a single case, and these included putative pathogenic mutations
(c.424G>A [p.Glu142Lys] and c.425A>G [p.Glu142Gly]) and the generalized-pustular-psoriasis mutation, c.413A>C (p.Glu138Ala);
these threemutations lie within the coiled-coil domain ofCARD14. The c.349G>A (p.Gly117Ser) familial-psoriasis mutationwas present
at a frequency of 0.0005 in cases of European ancestry. CARD14 variants led to a range of NF-kB activities; in particular, putative
pathogenic variants led to levels >2.53 higher than did wild-type CARD14. Two variants (c.511C>A [p.His171Asn] and c.536G>A
[p.Arg179His]) required stimulation with tumor necrosis factor alpha (TNF-a) to achieve significant increases in NF-kB levels. Transcrip-
tome profiling of wild-type and variant CARD14 transfectants in keratinocytes differentiated probably pathogenic mutations from
neutral variants such as polymorphisms. Over 20 CARD14 polymorphisms were also genotyped, and meta-analysis revealed an associ-
ation between psoriasis and rs11652075 (c.2458C>T [p.Arg820Trp]; p value ¼ 2.13 106). In the two largest psoriasis cohorts, evidence
for association increased when rs11652075 was conditioned on HLA-Cw*0602 (PSORS1). These studies contribute to our understanding
of the genetic basis of psoriasis and illustrate the challenges faced in identifying pathogenic variants in common disease.Introduction
Psoriasis is a chronic, inflammatory disease of the skin and
other organs. It affects approximately 2% of individuals of
European descent,1 and in up to 30% of cases, it is associ-
ated with chronic inflammatory psoriatic arthritis.2
Genome-wide association studies (GWASs) have identified
over 20 susceptibility loci for psoriasis.3–11 However, with
the exception of psoriasis susceptibility locus 1 (PSORS1
[MIM 177900]), for which the odds ratio (OR) is approxi-
mately 3.0,12,13 risk conferred by these loci is generally
small (ORs% 1.5). Moreover, less than 20% of disease vari-
ance has been explained.14,15 This implies that additional
low-risk loci, genetic interactions, or rare variants of large
effect account for the remaining variance.
In our accompanying paper, we identified rare, gain-of-
function mutations in caspase recruitment domain family,
member 14 (CARD14 [MIM 607211])16 in two large multi-
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issue of AJHG). We also identified a de novo mutation in
CARD14 in a child with early-onset, severe pustular psori-
asis (PSORP [MIM 614204]). These mutations are respon-
sible for the elusive psoriasis susceptibility locus 2 (PSORS2
[MIM 602723]) in chromosomal region 17q25. These
results led us to hypothesize that additional rare and
common variants in CARD14might contribute to psoriasis
and/or psoriatic arthritis in the general population.
Here, we identify and characterize 15 additional rare
missense variants within CARD14 and determine their
frequencies in a large cohort of approximately 6,000 psori-
asis cases and 4,000 controls. Statistical analyses revealed
an excess of rare variants in psoriasis cases relative to
controls. The potential pathogenicity of variants was
demonstrated by their ability to increase transcriptional
activation by nuclear factor of kappa light chain enhancer
in B cells (NF-kB) and to enhance production of a subset
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Table 1. Psoriasis Cases and Controls Included in this Study
Cohort Cohort Description Cases Controls
A St. Louis/Dallas/UCSF 676 570
B NPF (European) 486 154
C Utah 931 236variant within CARD14 was also associated with psoriasis,
and that evidence for association increased when this
locus was conditioned on the presence of PSORS1. Our
findings indicate that a range of NF-kB responses in the
skin are mediated by CARD14 and that a subset of rare
CARD14 variants leads to psoriasis and psoriatic arthritis.D Michigan 2,768 2,749
E Toronto 981 483
F Newfoundland 340 379
G Asians 194 193
H Combined European
(rows A–F)
6,182 4,571
I NPF (all samples) 976 758
Individuals were recruited from multiple institutions and organized into
cohorts, as shown in this table. Cohorts A–F are independent case/control
cohorts of Northern European ancestry. Cohort G includes samples of Asian
ancestry from the St. Louis/Dallas/UCSF (University of California, San Francisco)
and the NPF (National Psoriasis Foundation Victor Henschel Tissue Repository)
cohorts (cohorts A and B, respectively). Cohorts A–G include samples of known
ancestry. Cohort H lists all cases and controls contributed by the NPF, including
those of unknown ancestry. Demographic data were available only for approx-
imately half of the NPF samples.Subjects and Methods
Subjects
Cases and controls for sequencing and genotyping were
recruited from multiple institutions. Samples were organized
into cohorts as shown in Table 1. There were six cohorts of
European ancestry and one of Asian ancestry. Referring to Table
1, European cases in cohort A were recruited from either Wash-
ington University in St. Louis or the Department of Dermatology
at the University of California, San Francisco (UCSF). Controls in
cohort A were unaffected individuals who were over 20 years of
age and who had no family history of psoriasis; they were
recruited from the Texas Scottish Rite Hospital for Children or
from the Cardiovascular Research Institute and Center for
Human Genetics at the University of California, San Francisco
or they were CEU (Utah residents with Northern and Western
European ancestry from the CEPH collection) grandparents.
Cohort B samples were from the National Psoriasis Foundation
Victor Henschel Tissue Repository (NPF). Cases and controls in
cohort C were recruited from the Department of Dermatology
at the University of Utah. For cohorts A–C, psoriasis was diag-
nosed by a dermatologist.
Cohort D samples were recruited from the Department of
Dermatology at the University of Michigan. Cases had at least
two psoriatic plaques or a single plaque occupying at least 1% of
the total body surface outside the scalp. Individuals presenting
with only palmoplantar psoriasis, inverse psoriasis, or sebopsoria-
sis were excluded. Controls were at least 18 years of age and had no
personal or family history of psoriasis.
Cohort E samples were gathered from the University of Toronto
and Toronto Western Hospital. Cohort F samples were gathered
from the Department of Medicine, Division of Rheumatology,
Memorial University of Newfoundland. Psoriasis was diagnosed
by a dermatologist. When psoriatic arthritis was suspected, cases
were evaluated according to clinical history and rheumatologic
and radiologic evaluation. Control individuals showed no
evidence of psoriasis, psoriatic arthritis, or any other autoimmune
disease.
Asian samples in Cohort G were recruited from the Cardiovas-
cular Research Institute and Center for Human Genetics at the
University of California, San Francisco, from the University of
Toronto and Toronto Western Hospital and the Department of
Medicine, or from the NPF.
DNA was isolated from whole blood or saliva by standard
methods. Protocols were approved by local institutional review
boards. All subjects or their parents (if the subjects were minors)
provided informed consent.Sanger Resequencing and Genotyping
As a first pass, all coding exons of CARD14 (full-length, CARD14fl)
were resequenced in 192 psoriasis cases and 96 controls of Euro-
pean ancestry. Exons in which rare missense mutations were iden-
tified were resequenced in 95 more controls of European ancestry.The AmExon 4 of CARD14 was resequenced in an additional 1,856 cases
and 882 controls of European ancestry. Primers are available
upon request. Samples were genotyped with the Sequenom
MassARRAY at Washington University and by TaqMan at the
University of Michigan (Table S2, available online). All samples
from the NPF were genotyped, but only samples of known
ethnicity were included in statistical analyses.Expression Plasmids
Full-length CARD14sh (GenBank BC018142, coding for 740
amino acids) and CARD14cl (RefSeq NM_052819, coding for 434
amino acids) were cloned into pReceiver-M11 (Capital Biosci-
ences). The CARD14sh construct was subjected to in vitro muta-
genesis with the QuikChange Site-Directed Mutagenesis Kit
(Stratagene). The numbering of all CARD14 mutations in this
manuscript is based on RefSeq NM_024110.3. For rare, nonanno-
tated missense variants, constructs were generated with the
mutant allele. For polymorphisms (rare and common), constructs
were generated as follows (the allele and amino acid used are listed
in parentheses): rs115582620 (c.185A [p.Gln185]), p.Ser200Asn
(c.599A [p.Asn200]), rs146214639 (c.449G [p.Arg150]),
rs144475004 (c.526C [p.His176]), rs2066964 (c.930C [p.Ser547]),
rs34367357 (c.1042A [p.Ile585]), rs117918077 (c.2044T
[p.Trp682]), and rs151150961 (c.2140A [p.Ser714]). Full-length
CARD14fl was not available for subcloning. As a result, constructs
could not be created for rs144285237 (c.2919C>G [p.Asp973Gln])
or rs11652075 (c.2458C>T [p.Arg820Trp]).NF-kB Luciferase Reporter Assay
The NF-kB luciferase reporter assay was performed with the
pNFkB-luc system (Clontech) as described in our accompanying
manuscript.17 The CARD14cl clone was used as a negative control
in this assay because it lacks the sequence encoding the
CARD domain, which is necessary for CARD14-induced NF-kB
activation.erican Journal of Human Genetics 90, 796–808, May 4, 2012 797
Expression Profiling and qRT-PCR
HEK 001 cells (human-papillomavirus-16-transformed keratino-
cytes) were transfected with wild-type CARD14sh or expression
constructs encoding CARD14sh substitutions. Cells were cultured
for 24 hr, and then RNA was isolated with the miRNeasy kit
(QIAGEN). Global expression profiling of RNA from cells was
performed with the HumanHT-12 v4 Expression BeadChip (Illu-
mina). Experiments were conducted in compliance with MIAME
(minimum information about a microarray experiment) guide-
lines. Raw and normalized expression data are deposited in the
National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) as series GSE36381. 100 ng to 1 mg
of randomly primed total RNA was used for quantitative RT-PCR
(qRT-PCR) according to standard procedures. Expression levels
were normalized to 18S rRNA. Relative expression levels were
calculated as follows: 2 3 106((Ct 18S)(Ct CARD14)). We also normal-
ized expression levels in transfected cells to levels of FLAG to
correct for differences in transfection efficiency.Clustering of Variants on the Basis of Expression
Levels in Keratinocytes
On the basis of the NF-kB reporter assays, a subset of CARD14 vari-
ants were classified as (1) leading to enhanced basal NF-kB activa-
tion when they were compared to the effects of wild-type
CARD14sh (these are c.349G>A [p.Gly117Ser], c.413A>C
[p.Glu138Ala], c.424G>A [p.Glu142Lys], and c.425A>G
[p.Glu142Gly]), (2) leading to downregulation of NF-kB activation
(c.112C>T [p.Arg38Cys]), or (3) having no effect on NF-kB activa-
tion (these are c.185G>A [p.Arg62Gln] [rs115582620],
c.930G>C [p.Arg547Ser] [rs2066964], c.449T>G [p.Leu150Arg]
[rs146214639], c.854A>G [p.Asp285Gly], c.1778T>A
[p.Ile593Asn], c.2044C>T [p.Arg682Trp] [rs117918077], and
c.2140G>A [p.Gly714Ser] [rs151150961]). After performing
mRNA transcriptome analysis on cells that were transfected with
either wild-type CARD14sh or CARD14 variants, we found that
1,531 transcripts had at least a 2-fold change (up or down) in
expression as well as a significant p value in transfectants with
the CARD14 variants causing enhanced NF-kB activation relative
to transfectants with wild-type CARD14sh. The variants were
then clustered with the use of the reduced probe set and the R
(v2.10.1) randomForest package (v4.6-2). Random forests were
generated with 500 trees and unweighted classes, and importance
was calculated for a total of 10,000,000 forests. The probes were
then ranked from highest to lowest mean decrease in Gini. A
heat map of the clustering of the full set of variants was generated
with the top 30 probes.Pathway Analysis of the ‘‘CARD14 Pathogenic
Keratinocyte Signature’’
A list was generated of genes differentially expressed as a conse-
quence of the introduction of CARD14 psoriasis-specific alter-
ations into HEK 001 cells as described above. We obtained this
list, termed the ‘‘CARD14 pathogenic keratinocyte signature,’’ by
comparing the global transcriptomes of keratinocyte transfectants
with overtly pathogenic CARD14 substitutions (p.Gly117Ser,
p.Glu138Ala, p.Gly142Lys, and p.Glu142Gly) to those with
nonpathogenic substitutions (p.Leu150Arg [rs146214639],
p.Val191Leu, p.Asp285Gly, and wild-type CARD14sh). Expression
data from each sample were quantile normalized, log2 trans-
formed, and fitted to linear models in R (R v2.13.1; Biobase
v2.12.2; BeadArray v2.2.0; and limma v3.8.3). The contrast was798 The American Journal of Human Genetics 90, 796–808, May 4, 2defined as ‘‘pathogenic versus nonpathogenic,’’ and the t tests,
fold changes, and false-discovery-rate-corrected p values were
calculated with ImFit and eBayes. Given the overexpression of
the constructs, larger sample sizes would be required for the detec-
tion of significant group-wise effects. However, by taking the
genes with a nominal group-wise p value of 0.05 and ranking
them by fold change, we generated a list of the top 200 upregu-
lated and top 200 downregulated genes. This list was analyzed
with Ingenuity pathway analysis (IPA).Statistical Analysis
Analysis of variants was performed with PLINK.18 The variable
threshold test19 and a straightforward burden test for association
of rarevariantswithdiseasewereperformedwithPLINK/SEQversion
0.05. For both tests, we includedCARD14 variants withminor allele
frequencies of less than or equal to 0.01 among our controls of
northern European ancestry. This included the following 16
variants: c.112C>T (p.Arg38Cys), c.185G>A (p.Arg62Gln)
(rs115582620), c.349G>A (p.Gly117Ser) (altered in family PS117),
c.413A>C (p.Glu138Ala) (altered in generalized pustular psori-
asis17), c.424G>A (p.Glu142Lys), c.425A>G (p.Glu142Gly),
c.449T>G (p.Leu150Arg) (rs146214639), c.511C>A (p.His171Asn),
c.526G>C (p.Asp176His) (rs144475004), c.536G>A (p.Arg179His),
c.571G>T (p.Val191Leu), c.599G>A (p.Ser200Asn), c.854A>G
(p.Asp285Gly), c.1778T>A(p.Ile593Asn), c.2140G>A (p.Gly714Ser)
(rs151150961), and c.2919C>G (p.Asp973Gly) (rs144285237).
Meta-analysis of polymorphisms and generation of forest plots
were performed with R version 2.12.220 with the rmeta package.Results
Rare-Variant Screening
In our accompanying manuscript, we identified rare gain-
of-function CARD14 mutations that lead to psoriasis.17
These included the familial c.349G>A (p.Gly117Ser) muta-
tion in family PS1, affected by multiple cases of psoriasis
and psoriatic arthritis,21 and the de novo c.413A>C
(p.Glu138Ala) germline mutation in a case of childhood
generalized pustular psoriasis. To determine whether there
were additional rare variants predisposing to psoriasis in
CARD14, we resequenced all coding exons of CARD14
(full-length, CARD14fl) in over 192 psoriasis cases and 96
controls (see Subjects and Methods). This revealed ten
rare missense mutations in CARD14 (Figure 1, Table 2,
and Table S1): c.112C>T (p.Arg38Cys), c.185G>A
(p.Arg62Gln) (rs115582620), c.425A>G (p.Glu142Gly),
c.449T>G (p.Leu150Arg) (rs146214639), c.599G>A
(p.Ser200Asn), c.854A>G (p.Asp285Gly), c.1778T>A
(p.Ile593Asn), c.2044C>T (p.Arg682Trp) (rs117918077),
c.2140G>A (p.Gly714Ser) (rs151150961), and
c.2919C>G (p.Asp973Gln) (rs144285237). On the basis
of the observation that several rare mutations were
clustered in exon 4, which encodes part of the critical
coiled-coil domain, we reasoned that it might be
a mutation hotspot and resequenced an additional 1,800
cases and 900 controls for that exon. This revealed five
additional rare variants within CARD14: c.424G>A
(p.Glu142Lys), c.511C>A (p.His171Asn), c.526G>C012
Figure 1. CARD14 Protein Domains and Locations of Amino Acid Substitutions
Missense variants identified in CARD14 by resequencing are shown relative to key protein domains. Red outlining indicates increased
NF-kB activation by a variant (relative to wild-type); green outlining indicates reduced activation. Gold outlining indicates variants that
showed increased NF-kB activation only in response to TNF-a stimulation. SNPs and variants also identified in dbSNP135, which
includes data from the 1,000 Genomes Project and the National Heart, Lung, and Blood Institute (NHLBI) and National HumanGenome
Research Institute (NHGRI) Exome Project, are indicated with blue triangles. A polymorphism, rs114688446, was observed at the same
site as p.Ser200Asn, but a different substitution, p.Ser200Ile, was detected. SNPs used for meta-analysis are indicated with gray triangles.(p.Asp176His) (rs144475004), c.536G>A (p.Arg179His),
and c.571G>T (p.Val191Leu) (Figure 1, Table 2, and Table
S1). A search in dbSNP135 revealed that 8 of the 15 identi-
fied rare variants have not been previously annotated;
these eight are c.112C>T (p.Arg38Cys), c.424G>A
(p.Glu142Lys), c.425A>G (p.Glu142Gly), c.511C>A
(p.His171Asn), c.536G>A (p.Arg179His), c.571G>T
(p.Val191Leu), c.599G>A (p.Ser200Asn), c.854A>G
(p.Asp285Gly), and c.1778T>A (p.Ile593Asn). Further-
more, this search revealed that the c.349G>A
(p.Gly117Ser) and c.413A>C (p.Glu138Ala) mutations
have also not been previously annotated.
Population-Based Frequency Estimates of Rare
Variants
We determined the frequencies of all rare CARD14 vari-
ants, including those encoding the familial p.Gly117Ser
alteration (causing psoriasis and/or psoriatic arthritis)
and the p.Glu138Ala alteration (causing generalized
pustular psoriasis), by high-throughput genotyping seven
independent case/control cohorts (>10,000 individuals;
Tables 1 and 2 and Tables S1 and S2). This revealed two
other unrelated psoriasis cases with the CARD14
c.349G>A (p.Gly117Ser) mutation; one woman was from
the NPF repository and was diagnosed with psoriasis at
10 years old and psoriatic arthritis at 20 years old, andThe Amanother woman was from Utah and had a history of psori-
asis, which was diagnosed at 65 years old. This latter
woman transmitted the mutation to her daughter, who
developed psoriasis at age 32. This mutation was also de-
tected in a male NPF control for whom additional data
(e.g., ethnicity, age, and family history of psoriasis) were
not available. None of these individuals harbored the
SLC26A1122 (solute carrier family 26, member 11,
[SLC26A11 (MIM 610117)]) c.365A>G (p.Tyr122Cys)
mutation, which cosegregated with c.349G>A
(p.Gly117Ser) in family PS1,17 providing evidence that
these variants can arise independently. Numbering of the
SLC26A11mutation is based on RefSeq NM_001166347.1.
In total, the frequency of the CARD14 c.349G>A
(p.Gly117Ser) mutation in cases of European ancestry was
0.0005. The CARD14 c.349þ5G>Amutation, which segre-
gated with psoriasis in a large multiply affected Taiwanese
family,17 was not detected in any other cases or controls.
However, given the relatively small number of Asian
samples screened, we were not well powered to detect vari-
ants at low frequencies in that population. The mutation
encoding p.Glu138Ala seen in the single pustular psoriasis
case was also not seen in any other cases or controls.
Five rare CARD14 variants (encoding p.Arg38Cys,
p.Glu142Gly, p.Glu142Lys, p.Val191Leu, andp.Asp285Gly;
Figure 1 andTables S1 andS2)were seen inonlyonecase anderican Journal of Human Genetics 90, 796–808, May 4, 2012 799
Table 2. Characteristics and Frequencies of CARD14 Coding Variants
CARD14
Exon
cDNA Mutation
and Corresponding
Protein Change
Protein
Domain
PolyPhen227-Predicted
Effect on Protein
Function
Effect on NF-kB
Activation (FC
versus Wild-Type
CARD14sh)
Allele Frequency
in Cases (Number
Sampled)
Allele Frequency
in Controls (Number
Sampled)
2 c.112C>T (p.Arg38Cys) CARD probably damaging 0.11 0.00019 (2,691) 0 (1,271)
2 c.185G>A (p.Arg62Gln)
(rs115582620)
CARD benign 1.06 0.0014 (3,284) 0.00084 (1,797)
3 c.349G>A (p.Gly117Ser) none possibly damaging 3.71 0.00023 (6,630) 0 (4,731)
3 c.349þ5G>A none NA ND 0 (2,871) 0 (1,339)
4 c.413A>C (p.Glu138Ala) coiled-coil probably damaging 8.95 0.00015 (3,488) 0 (1,902)
4 c.424G>A (p.Glu142Lys) coiled-coil probably damaging 4.03 0.00012 (4,107) 0 (1,874)
4 c.425A>G (p.Glu142Gly) coiled-coil probably damaging 5.00 0.00019 (2,848) 0 (1,451)
4 c.449T>G (p.Leu150Arg)
(rs146214639)
coiled-coil probably damaging 1.79 0.0025 (6,140) 0.0016 (4,614)
4 c.511C>A (p.His171Asn) coiled-coil benign 0.68 (5.95 with
TNF-a stimulation)
0.00025 (4,077) 0 (1,858)
4 c.526G>C (p.Asp176His)
(rs144475004)
coiled-coil probably damaging 2.78 0.00056 (3,575) 0.00062 (1,609)
4 c.536G>A (p.Arg179His) coiled-coil probably damaging 1.38 (2.19 with
TNF-a stimulation)
0.00025 (4,061) 0.00027 (1,848)
4 c.571G>T (p.Val191Leu) coiled-coil benign 1.02 0.00014 (3,575) 0 (1,613)
4 c.599G>A (p.Ser200Asn) coiled-coila benign 0.67 0.011 (6,163) 0.0084 (4,624)
6 c.854A>G (p.Asp285Gly) none possibly damaging 1.14 0.00019 (2,673) 0 (1,467)
13 c.1778T>A (p.Ile593Asn) PDZ probably damaging 1.30 0.00024 (2,049) 0.00048 (1,039)
15 c.2044C>T (p.Arg682Trp)
(rs117918077)
SH3 probably damaging 0.95 0.013 (2,169) 0.012 (1,042)
15 c.2140G>A (p.Gly714Ser)
(rs151150961)
SH3 benign 1.02 0.0021 (2,105) 0.0014 (1,038)
21 c.2919C>G (p.Asp973Glu)
(rs144285237)
GUK benign NDb 0.0024 (5,177) 0.0015 (4,099)
CARD14missense variants are listed with details on their locations in critical CARD14 protein domains, their predicted effect on protein function from PolyPhen2,27
their effect on NF-kB activation (fold change compared to unstimulated wild-type CARD14sh; see also Figure 3), and frequencies in unrelated cases and controls of
European ancestry. The number of individuals screened is in parenthesis. The following abbreviations are used: FC, fold change; and ND, not done.
aThe p.Ser200 residue lies within a 6 bp sequence separating two predicted coiled-coil regions and thus could be considered part of an overarching coiled-coil
domain. Also, variant rs114688446 was identified at this location in dbSNP, but the amino acid change (p.Ser200Ile) was different.
bThe impact of p.Asp973Glu on NF-kB activation could not be tested because it is exclusive to CARD14fl, for which a full-length cDNA clone was unavailable.
Additional data on these variants are presented in Table S1.in no controls. The variant encoding p.His171Asn was only
seen in two psoriasis- and psoriatic-arthritis-affected cases
from Newfoundland and in no controls. We performed
a simple burden test and a variable threshold test19 to
compare the distribution of rare variants in cases and
controls. These tests provided evidence of an excess of rare
CARD14 variants in cases versus controls (burden test p
value ¼ 0.0015; variable threshold test p value ¼ 0.0053).
Common-Variant Association Tests
Resequencing validated several common missense poly-
morphisms described in dbSNP: rs2066964, rs34367357,
and rs11652075. We genotyped these and 20 other previ-
ously described SNPs in our seven psoriasis case/control
cohorts (Table S2) and looked for association with psori-
asis. Most variants were present at similar frequencies in800 The American Journal of Human Genetics 90, 796–808, May 4, 2cases and controls. However, three missense SNPs
(rs2066964, rs34367357, and rs11562075) within
CARD14 and rare variant c.599G>A (p.Ser200Asn)
provided evidence of association with psoriasis in some
of the cohorts (Table S2). A meta-analysis of these four
missense variants was performed for the six cohorts of
European ancestry (Figure 2 and Figure S1). This revealed
further evidence of association between psoriasis and
rs11652075 (c.2458C>T [p.Arg820Trp]) (fixed effects p
value ¼ 2.1 3 106, OR ¼ 0.87 [0.83–0.92]; random effects
p value ¼ 0.031, OR ¼ 0.86 [0.75–0.99]); c.2458C was the
risk allele (Figures 2A and 2B). This SNP, as well as the
same risk allele, was also associated with psoriasis in Asians
(p value ¼ 0.0029, OR ¼ 0.64 [0.48–0.86]). The meta-anal-
ysis also revealed evidence of association with p.Ser200Asn
(fixed and random effects p values ¼ 0.05, OR ¼ 1012
Figure 2. Meta-Analyses of rs11652075 and p.Ser200Asn across Six Case/Control Cohorts of European Ancestry
The results of the fixed- (A) and random-effects (B) meta-analyses for rs11652075 (c.2458C>T [p.Arg820Trp]) and the fixed-effects meta-
analysis for p.Ser200Asn (c.599G>A) (C) are shown. The random-effects meta-analysis for p.Ser200Asn was identical to that of the fixed-
effects meta-analysis and is therefore not pictured. Forest plots indicate the direction of effect, relative weight, and confidence interval
for the odds ratio of this SNP in each cohort. The number of cases and controls successfully genotyped in each cohort is shown, and the
meta-analysis OR and p value are listed below each plot. The following abbreviations are used: OR, odds ratio; and C.I., confidence
interval.[1.3–1.82]); the rare c.599A allele increased psoriasis risk
(Figure 2C). However, this would not be significant if it
were adjusted for multiple testing.
Because of the large effect of HLA-Cw*0602 from the
major histocompatibility complex (MHC) class I region
(PSORS1),12,13 we investigated its connection with the
four CARD14 variants described above. In the Michigan
and Utah psoriasis cohorts, rs11652075 was found to
have a higher association with psoriasis when it was
conditioned on HLA-Cw*0602 (p value of rs11652075
alone ¼ 0.023 (Michigan), 0.017 (Utah); stratified on
HLA-Cw*0602, p value ¼ 0.0021 (Michigan), 0.0086
(Utah); Table S3). No such evidence was observed with
the other variants.
Effect of Variants on CARD14 Function In Vitro
CARD14 encodes a 1,004 amino acid protein that activates
NF-kB.16 In our companion paper, we observed that
compared to wild-type CARD14, the familial p.Gly117SerThe Amand de novo p.Glu138Ala substitutions lead to enhanced
NF-kB activation (3.71- and 8.95-fold enhancement,
respectively). To test the effect of rare variants described
here on this activity, we again used an NF-kB luciferase
reporter assay. Several rare variants (p.Glu142Lys,
p.Glu142Gly, and p.Asp176His [rs144475004]) in the
coiled-coiled domain increased NF-kB activation two to
five times more than did wild-type CARD14sh (Table 2,
Figure 3A). The p.Arg38Cys, p.His171Asn, and p.Ser200Asn
substitutions led to less NF-kB activation than did
CARD14sh, but compared to wild-type CARD14sh, other
rare variants and the CARD14 missense polymorphisms
(p.Arg62Gln [rs115582620], p.Arg547Ser [rs2066964],
p.Arg682Trp [rs117918077]) did not significantly alter
NF-kB activation levels (Table 2, Figure 3A). As discussed
below, variants that increased NF-kB activation at least
2.53 more than that seen with CARD14sh also induced
greater upregulation of psoriasis-associated genes. Relative
to wild-type CARD14sh, variants that resulted in a moreerican Journal of Human Genetics 90, 796–808, May 4, 2012 801
Figure 3. Effect of Wild-Type and Altered
CARD14 on NF-kB Activation
HEK 293 cells were transfected with the construct
that codes for CARD14sh, the same construct
harboring one of the rare variants shown, or
a construct that codes for CARD14cl and lacks
theCARDdomain.NF-kB activitywas determined
bymeasuring relative luciferase activity. Transfec-
tion efficiency was controlled for by first normal-
izing all values to Renilla expression, and activity
of the empty background vector, pTAL-luc, was
controlled for by adjusting the values. Change in
NF-kB activity relative to the background vector
was determined for each variant (y axis, NF-kB
activity). Every data point represents the average
value of three replicates. Error bars represent the
standard deviation of replicates. For experiments
involving TNF-a stimulation, treated cells were
exposed to 20 ng/ml TNF-a in culture media for
24 hr. Asterisks show results from two-tailed,
unpaired student’s t tests comparingNF-kB activa-
tion induced by the indicated variant to either
that of unstimulated cells with CARD14sh (A) or
that of TNF-a-stimulated cells with CARD14sh
(B). *p% 0.05, **p% 0.01, and ***p% 0.001.modest increase in NF-kB activation, those that reduced
NF-kB activation, and those that did not change it did
not induce upregulation of those genes to the same degree.
Therefore, when compared with the level of NF-kB activa-
tion caused by wild-type CARD14, a 2.53 or greater
increase in NF-kB activation is predictive of putative path-
ogenic CARD14 amino acid substitutions.
Onset of psoriatic lesions is thought to be triggered by an
inflammatory stimulus. We therefore examined the effects
of wild-type and variant CARD14 on NF-kB activation after
stimulation with tumor necrosis factor alpha (TNF-a).
Compared with unstimulated CARD14sh, TNF-a-stimu-
lated p.His171Asn and p.Arg179His resulted in a 5.95-
and a 2.95-fold increase in NF-kB activation, respectively;
compared with TNF-a-stimulated CARD14sh, TNF-a-stim-
ulated p.His171Asn and p.Arg179His resulted in a 2.87-
and a 1.06-fold increase in NF-kB activation, respectively
(Table 2 and Figure 3B, discussed further below).
Effect of CARD14 Substitutions on Keratinocyte Gene
Expression
We have shown that CARD14 is localized in keratinocytes
and that the familial and pustular-psoriasis variants
(p.Gly117Ser and p.Glu138Ala, respectively) lead to
enhanced production of some chemokines and other tran-
scripts that are upregulated in psoriatic skin.17 To evaluate
the effect of the additional rare variants on transcription in
keratinocytes, we transfected all altered constructs into the
keratinocyte cell line HEK 001. The transcriptome of each
transfectant was then evaluated after 24 hr by interroga-802 The American Journal of Human Genetics 90, 796–808, May 4, 2012tion with Illumina bead arrays. A heat
map with 30 probes (see Subjects and
Methods, random forest classification) re-
vealed clustering of the p.Glu142Lys andp.Glu142Gly transfectants with those with the
p.Gly117Ser and p.Glu138Ala alterations (Figure 4). The
p.Glu138Ala substitution clustered at the extreme end of
other pathogenic variants and on its own branch of the
tree. This might be expected given the severity of the
disease in the child (who has generalized pustular psori-
asis) in whom it was found.
Within this heat map, the following 13 genes were upre-
gulated in keratinocytes transfected with pathogenic
substitutions: superoxide dismutase 2, mitochondrial
(SOD2 [MIM 147460]); interleukin 6 (interferon, beta 2
[IL6 (MIM 147620)]); colony stimulating factor 2 (granulo-
cyte-macrophage [CSF2 (MIM 138960)]); interleukin 8 (IL8
[MIM 146930]); matrix metallopeptidase 9 (gelatinase B,
92kDa gelatinase, 92kDa type IV collagenase [MMP9
(MIM 120361)]); BRF2, subunit of RNA polymerase III
transcription initiation factor, BRF1-like (BRF2 [MIM
607013]); chemokine (C-C motif) ligand 20 (CCL20
[MIM 601960]); solute carrier family 7 (cationic amino
acid transporter, yþ system), member 2 (SLC7A2 [MIM
601872]); oxidized low density lipoprotein (lectin-like)
receptor 1 (OLR1 [MIM 602601]); interleukin 36, gamma
(IL36G [MIM 605542]); guanylate binding protein 2, inter-
feron-inducible (GBP2 [MIM 600412]); tumor necrosis
factor, alpha-induced protein 2 (TNFAIP2 [MIM 603300]);
and tumor necrosis factor (TNF [MIM 191160]). We used
g:Profiler23 to look for specific functions of these genes.
The most significant Gene Ontology24 terms associated
with this group of genes included: immune-system
process/development, hematopoietic- or lymphoid-organ
E
1
3
8
A
G
1
1
7
S
E
1
4
2
K
E
1
4
2
G
G
7
1
4
S
S
2
0
0
N
D
1
7
6
H
R
1
7
9
H
C
a
rd
s
h
R
3
8
C
R
6
2
Q
I5
9
3
N
H
1
7
1
N
R
6
8
2
W
L
1
5
0
R
V
1
9
1
L
D
2
8
5
G
R
5
4
7
S
MDK
SOD2
FKBP1A
MYL12A
TNFAIP2
GBP2
TNF
IL36G
OLR1
CLCF1
SLC7A2
MMP9
CCL20
BRF2
LOC401537
TBL3
CABLES1
NOP14
SMARCB1
ATP5D
IL8
IL8
CSF2
IL6
SOD2
LOC552889
ALKBH2
LGALS3BP
EPHA2
CHD4
−2 −1 0 1 2 3
Figure 4. Heat Map Generated after Transcriptome Analysis of Wild-Type and Mutant CARD14 Transfectants
Cells were transfected with CARD14cl, wild-type CARD14sh, or variant CARD14 expression constructs. After 24 hr, RNA was extracted
and used for the interrogation of Illumina bead arrays. A subset of differentially expressed genes was used for clustering of CARD14 vari-
ants (see Subjects and Methods).development, and response to lipopolysaccharide/bacte-
rium/molecule of bacterial origin. IL6, MMP9, and BRF2
have also been implicated in cell migration and could
mediate immune cell infiltration into the skin. CSF2, IL8,
and SLC7A2 have been specifically implicated in myeloid
leukocyte activation. Psoriasis is a disease of keratinocyte
and immune cell proliferation, and genes involved in cell
proliferation include SOD2, IL6, CSF2, and IL8. Other
terms included response to wounding (SOD2, IL6, IL8,
CCL20, SLC7A2, and OLR1), nitric oxide biosynthetic
process (SOD2, IL6, and SLC7A2), and antiapoptosis
(SOD2, IL6, and CSF2). IL6 and CSF2 are implicated in
the regulation of the JAK-STAT pathway, and IL6, IL8,
andMMP9 are implicated in angiogenesis. Genes involved
in the response to biotic stimuli include SOD2, IL6, IL8,
MMP9, and CCL20. Psoriasis increases risk of cardiovas-
cular disease,25,26 and five of these genes have been impli-
cated in the development of the cardiovascular system
(SOD2, IL6, IL6, MMP9, and TNFAIP2). Upregulation ofThe Amthese thirteen genes thus constitutes a pathogenic psori-
atic signature.
Twovariants clustered together: c.526G>C(p.Asp176His)
(rs144475004) and c.536G>A (p.Arg179His). Both amino
acid substitutions were predicted to be damaging by Poly-
Phen2,27 and both lead to upregulation of NF-kB activation
(2.78- and 1.38-fold increases, respectively). In the case of
p.Arg179His, TNF-a was required for NF-kB activation to
achieve pathogenic levels; compared with unstimulated
CARD14sh andTNF-a-stimulatedCARD14sh, TNF-a-stimu-
lated p.Arg179His produced a 2.95- and a 1.06-fold increase,
respectively. Both variants were seen in a small number of
cases and controls (4:2 and 2:1, respectively).
Three other constructs clustered in the same branchwith
p.Asp176His (rs144475004) and p.Arg179His. These
included wild-type CARD14sh, c.2140G>A (p.Gly714Ser)
(rs151150961), and c.599G>A (p.Ser200Asn). However,
the latter three did not induce expression of the patho-
genic psoriatic signature described above to the sameerican Journal of Human Genetics 90, 796–808, May 4, 2012 803
degree as the overtly pathogenic variants. One noteworthy
example of this is that the IL8 expression produced by
these three constructs was much lower than that seen
with the pathogenic variants. Moreover, clustering of these
constructs was due to other transcripts that are not consid-
ered part of the pathogenic signature. Other variants ex-
hibited reduced levels of genes in this psoriasis signature,
even when compared to wild-type CARD14sh.
We confirmed altered expression of all thirteen tran-
scripts (SOD2, IL6, CSF2, BRF2, MMP9, IL8, CCL20,
SLC7A2, OLR1, IL36G, GBP2, TNFAIP1, and TNF) by qRT-
PCR (Figure S2).
We also performed a group-wise comparison of the
global expression profiles of the overtly pathogenic substi-
tutions (p.Gly117Ser, p.Glu138Ala, p.Glu142Lys, and
p.Glu142Gly) and several nonpathogenic variants
(p.Leu150Arg [rs146214639], p.Val191Leu, p.Asp285Gly,
and wild-type CARD14sh). The top 200 upregulated and
top 200 downregulated genes were identified (see Subjects
and Methods), and pathway analysis was performed with
IPA (Table S4). A number of cytokine signaling pathways
were significant (including IL-17 signaling, IL-6 signaling,
and TNFR2 signaling). Also significant were communica-
tion between innate and adaptive immune cells, dendritic
cell maturation, mTOR signaling, notch signaling, and
atherosclerosis signaling pathways. This latter pathway is
interesting given the association between psoriasis and
other systemic comorbidities, including cardiovascular
disease.25,26
A comparison of these results with a published psoriasis
transcriptome28 revealed that a number of these pathways
are significantly represented in both groups. For example,
the atherosclerosis signaling pathway, the NF-kB signaling
pathway, and many of the cytokine signaling pathways
were significant in both the published psoriasis transcrip-
tome and the CARD14 pathogenic keratinocyte signature
(Table S4). These results indicate that some of the pathways
upregulated in keratinocytes in which CARD14 harbors
a pathogenic substitution are also upregulated in classic
psoriatic skin. This suggests that altered keratinocyte acti-
vation might significantly contribute to the transcriptome
signatures in classic psoriasis lesions.Discussion
Here, we describe a spectrum of rare and common varia-
tion within CARD14, an activator of NF-kB16 in skin
epidermis, and we demonstrate enrichment of rare vari-
ants in cases by using two independent statistical tests.
The burden test, which performs a straightforward
comparison of the number, or ‘‘burden,’’ of rare variants
in cases and controls, provided a p value of 0.0015. The
variable threshold test,19 which compares rare variants
subject to a variable allele-frequency threshold in cases
and controls, gave a p value of 0.0053. We also demon-
strate that pathogenic alterations were enriched in the804 The American Journal of Human Genetics 90, 796–808, May 4, 2coiled-coil domain of CARD14. This domain is predicted
to be involved in the oligomerization of CARD14 with
other proteins and the formation of its active conforma-
tion.29,30 Interestingly, although some of the rare variants
we identified have been annotated in dbSNP135, none
of the putative pathogenic alterations are annotated.
A coding polymorphism in CARD14, rs11652075
(p.Arg820Trp), and c.599G>A (p.Ser200Asn) were also
associated with psoriasis in several large cohorts. In the
two largest psoriasis cohorts, evidence of association
between psoriasis and rs11652075 increased when
rs11652075 was conditioned on PSORS1.
Two rare variants, c.424G>A (p.Glu142Lys) and
c.425A>G (p.Glu142Gly), were identified in cases but
not in controls and manifested as overtly causing of
disease. Compared with wild-type CARD14sh, they signif-
icantly enhanced NF-kB activation (4.03- and 5.00-fold
enhancement, respectively), and they clustered with
p.G117Ser and p.Glu138Ala after transfection into the ker-
atinocyte line HEK 001 and global expression profiling.
The c.424G>A (p.Glu142Lys) variant was identified in
a Caucasian male who was diagnosed with psoriasis at
42 years of age and who responded well to treatment
with UV light and a topical mixture of corticosteroid and
a vitamin D analog. The c.425A>G (p.Glu142Gly) variant
was found in a Caucasian male who was diagnosed with
psoriasis in infancy and whose father also had psoriasis.
He experienced a partial remission of psoriasis with meth-
otrexate treatment. It is noteworthy that after these vari-
ants were stimulated with TNF-a, levels of NF-kB activation
induced by these variants and the pustular-psoriasis substi-
tution, p.Glu138Ala, decreased at the 24 hr mark. This
suggests that at this time, downregulation of the NF-kB
response might have been initiated in our cell-culture
system, which merits further study. Both of these variants
lie in the coiled-coil domain of CARD14, as does the de
novo pustular-psoriasis substitution, p.Glu138Ala.
Compared with wild-type CARD14sh, a third variant,
p.Asp176His (rs144475004), leads to enhanced NF-kB acti-
vation. However, its frequency was similar in cases and
controls, and it didn’t increase NF-kB activity in vitro as
much as other variants did. Hence, it might lie below the
NF-kB-activation threshold required for disease. Alterna-
tively, disease might require a specific stimulus or interac-
tion with a second genetic factor. Other variants such as
p.Arg38Cys and p.Ser200Asn exhibited significantly less
NF-kB activation than did wild-type CARD14sh. Previous
studies have shown that decreased activation of NF-kB,
much like increased activation, can induce inflammation
and epidermal hyperplasia.31,32 It might be interesting to
examine clinical features, such as inflammation after skin
wounding, of individuals with these variants. However, it
should be noted that the p.Arg38Cys and p.Ser200Asn
substitutions did not induce expression of the pathogenic
psoriasis signature when transfected into keratinocytes.
Thus, although we cannot completely rule out a role for
these variants in some aspects of disease, they are neither012
overtly pathogenic nor likely to be causative for initiation
of psoriasis.
Two variants, p.His171Asn and p.Arg179His, required
stimulation with TNF-a to achieve maximal levels of
NF-kB activation. The p.Arg179His substitution was
observed in two unrelated cases from Toronto and one
control. The cases included a female who was diagnosed
with psoriasis at 40 years of age and a male who was
diagnosed with psoriasis at 64 years of age and who
had a family history of psoriasis. The female responded
well to oral and topical steroids, but the male was not
treated.
The p.His171Asn alteration was seen in two unrelated
psoriasis- and psoriatic-arthritis-affected individuals from
Newfoundland and was not seen in controls. One indi-
vidual was diagnosed with psoriasis at 40 years of age
and psoriatic arthritis at 41 years of age and had a family
history of psoriasis. The second individual was diagnosed
with psoriasis at 55 years of age after being diagnosed
with psoriatic arthritis at 53 years of age. The identification
of the c.511C>A (p.His171Asn) variant in only the
Newfoundland population suggests that it arose as a
result of a founder effect in this population, but confirm-
ing this will require further studies. Inspection of the geno-
types of 13 polymorphisms in a 75 kb region harboring
CARD14 revealed a shared haplotype that is common in
cases and controls from the Newfoundland cohort and
our other case/control cohorts from the United States
(e.g., St. Louis/Dallas/UCSF, Michigan, and Utah). There-
fore, further evidence of a founder effect for the
p.His171Asn substitution seen in these two cases was not
possible.
The altered transcriptome signature with pathologic
substitutions included upregulation of psoriasis-specific
transcripts SOD2, IL6, CSF2, IL8, MMP9, BRF2, CCL20,
SLC7A2, OLR1, IL36G, GBP2, TNFAIP2, and TNF. Expres-
sion of these molecules is expected to be an early event
in the pathogenesis of psoriasis. Many of these genes
have been implicated in immune-system development.
However, BRF2 is implicated in the development of squa-
mous cell carcinoma of the lung.33 This suggests that it
might have global effects on the transcriptional profile of
squamous cell epithelia in general and might help elicit
a wound-healing or regenerative response in psoriatic ker-
atinocytes.
Despite the dramatic effects of some CARD14 variants as
keratinocyte transfectants, there was a wide range of
phenotypes, even among individuals who carried the
same substitution. This suggests that in many instances,
the variable phenotypes are likely to be due to genetic
background and/or environmental factors. For example,
affected members of family PS1 all harbor the c.349G>A
(p.Gly117Ser) mutation, but they have variable ages of
onset (ranging from infancy to 83 years of age) and vari-
able levels of disease severity, including the presence of
psoriatic arthritis. Similarly, age of onset and response to
treatment differed among individuals with the putativeThe Ampathogenic variants from the coiled-coil domain
(p.Glu142Lys, p.Glu142Gly, and p.Glu138Ala).
However, there might be some genotype-phenotype
correlations because the pustular-psoriasis substitution,
p.Glu138Ala, led to the most severe phenotype (in terms
of both clinical presentation and increased NF-kB activa-
tion) relative to that produced by wild-type CARD14sh.
The child with this alteration presented with a spectrum
of plaque-type lesions, but she mostly presented with
pustular lesions. This implies that some forms of plaque
psoriasis might be pathogenetically linked to pustular
psoriasis at the severe end of the disease spectrum. The
child’s lesions also exhibited a pronounced infiltration of
neutrophils. Interestingly, in keratinocyte transfectants
with this CARD14 substitution, there was a higher level
of IL8 than there was with other variants, which could
lead to higher levels of neutrophil infiltration. The obser-
vation that the p.Glu138Ala alteration led to the most
severe clinical phenotype and induced the greatest
increase in NF-kB activation and upregulation of psori-
asis-associated transcripts suggests that the phenotype of
psoriasis could, in some cases, be predicted by the detec-
tion of pathogenically increased levels of NF-kB activation
and signaling. How the CARD14 substitutions translate to
variable levels of chemokine activation and how genetic
background and environment trigger variable phenotypes
are important areas for further study.
CARD14 missense variants rs11652075 (c.2458C>T
[p.Arg820Trp]) and c.599G>A (p.Ser200Asn) were associ-
ated with psoriasis in cohorts of European ancestry. In
the Asian cohort, the c.2458T>C polymorphism was also
associated with psoriasis, but c.599G was monomorphic.
CARD14 was not shown to be associated with psoriasis in
a previous GWAS.8 However, none of the polymorphisms
with evidence of association with psoriasis in this study
were included in that GWAS and would not have been
likely to exceed genome-wide significance if they had
been. From the PSORS2 region of linkage, the SNP with
the most significant p value in the GWAS was rs7216577
(p value ¼ 0.00261).8 That SNP is located within an intron
of SLC26A11 and might regulate levels of CARD14mRNAs
in the skin. However, rs11652075, although not on the
Perlegen microarray in the CASP-GWAS,8 was part of the
HapMap-based imputed dataset that was used for the asso-
ciation analyses in that study. Its association p value was of
nominal significance (p ¼ 0.039, OR ¼ 1.10 for the C risk
allele reported here) and would not have been reported
because it was considerably below the threshold for
genome-wide significant association.
PSORS2 was originally identified by linkage,21,34 and our
studies with a common missense SNP (rs11652075) also
indicate that it can be associated with psoriasis. Linkage
and association have also been seen in some genes for
other common diseases, e.g., NOD2 (nucleotide-binding
oligomerization domain containing 2, [MIM 605956] in
inflammatory bowel disease (IBD1 [MIM 266600])35–37
and CFH (complement factor H, [CFH (MIM 134370)]) inerican Journal of Human Genetics 90, 796–808, May 4, 2012 805
age-related macular degeneration (ARMD1 [MIM
603075]).38,39
In two cohorts of European ancestry, evidence of associ-
ation between psoriasis and rs11652075 increased when
the PSORS1 variantHLA-Cw*0602was included as a covari-
ate, suggesting a genetic connection between PSORS1 and
PSORS2. This variant resides in the CARD14fl C-terminal
GUK domain, which is predicted to relay external signals
to the cellular milieu.16 This could explain the possible
genetic connection because antigen stimulation via
PSORS1might increase the risk of psoriasis by upregulating
signaling through the CARD14 pathway. This is consistent
with the fact that CARD14 affects signaling downstream of
antigen stimulation. However, it is important to note that
the PSORS1 risk variant, HLA-Cw*060240, was not present
in the affected members of the 17q-linked multiplex fami-
lies, the pustular-psoriasis case described previously,17 or
the cases with the p.Glu142Lys or p.Glu142Gly variants,
indicating that rare CARD14 variants can be sufficient to
lead to disease.
Our study illustrates some of the difficulties in searching
for rare variants associated with common disease, even
with an established gene. For example, it is not always
easy to differentiate pathogenic rare variants from others
when their numbers are very small. This also has an impact
on the detection of gene-gene or gene-environment inter-
actions. Moreover, it is sometimes necessary to recreate the
cellular milieu (e.g., an inflammatory stimulus in the case
of CARD14) when one attempts to differentiate disease-
causing variants from neutral variants through functional
studies. Nevertheless, our findings provide evidence that
some rare CARD14 variants predispose to psoriasis and,
possibly, to psoriatic arthritis, and they suggest that
common variants in this region might also predispose to
disease. They illustrate the challenges faced in identifying
truly pathogenic rare variants in common disease and
contribute to our understanding of the genetic basis of
psoriasis.Supplemental Data
Supplemental Data include two figures and three tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
This work was supported by grants from the National Institutes of
Health (NIH): AR050266 and 5RC1AR058681 (A.M.B.),
T32AR007279 (E.D.O.R.), T32HL083822 and T32 GM07200
(C.T.J), AR060222 (M.A.L), T32HG000045 (C.E.J), and
K08AR057763 (W.L.). J.T.E., R.N., and P.S. were supported by
NIH grants R01 AR042742, R01 AR050511, and AR054966 and
by the Babcock Memorial Trust. J.T.E. is supported by the Ann
Arbor Veterans Affairs Hospital. R.G.M. is supported by the Intra-
mural Research Programs of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases. Additional funding came from
the Arthritis Society of Canada, the Atlantic Innovation Fund, the
Canadian Institute of Health Research, the Arthritis Society, the806 The American Journal of Human Genetics 90, 796–808, May 4, 2Dana Foundation, and the Academia Sinica and National Science
Council (National Clinical Core, National Genotyping Core) of
Taiwan. The authors thank the many individuals with psoriasis
and the controls who participated in this study. We thank Linus
Schwantes-An, Weimin Duan, and Nancy Saccone for advice on
statistical analyses. We also thank Mayte Suarez-Farinas for biosta-
tistical assistance, Haoyan Chen, Olivia Lai, Fawnda Pellet, and
M.J. Malloy for assembling the control population, Pui-Yan
Kwok for sample procurement, Trilokraj Tejasvi for clinical evalu-
ation of study subjects, Nikki Plass for patient scheduling and
study logistics, Damaris Garcia for the management of samples,
andDebbie Stone andDawnChapelle for patient care.Mike Lovett
provided helpful comments on the manuscript. The authors are
indebted to the National Psoriasis Foundation for continuing
support during the course of this study.
Received: December 27, 2011
Revised: February 29, 2012
Accepted: March 13, 2012
Published online: April 19, 2012Web Resources
The URLs for data presented herein are as follows:
1,000 Genomes Project, http://www.1000genomes.org
dbSNP135, http://www.ncbi.nlm.nih.gov/projects/SNP/
g:Profiler, http://biit.cs.ut.ee/gprofiler/index.cgi
Gene Ontology, http://www.geneontology.com
Ingenuity Pathway Analysis (IPA), http://www.ingenuity.com/
Microarray Gene Expression Data Society (MIAME), http://www.
mged.org/Workgroups/MIAME/miame_checklist.html
NCBI Gene Expression Omnibus (GEO), http://www.ncbi.nlm.
nih.gov/geo/
NCBI Reference Sequence (RefSeq), http://www.ncbi.nlm.nih.
gov/RefSeq/
NHLBI/NHGRI Exome Project, http://exome.gs.washington.edu/
Online Mendelian Inheritance in Man (OMIM), http://omim.org
PLINK, http://pngu.mgh.harvard.edu/purcell/plink/
PLINK/SEQ version 0.05, http://atgu.mgh.harvard.edu/plinkseq/
PolyPhen-2.0, http://genetics.bwh.harvard.edu/pph2/
R, http://www.R-project.org
rmeta, http://cran.r-project.org/web/packages/rmeta/index.html
SequenomARRAY,http://hg.wustl.edu/info/Sequenom_description.
html
SIFT, http://sift.jcvi.org/References
1. Lowes, M.A., Bowcock, A.M., and Krueger, J.G. (2007). Patho-
genesis and therapy of psoriasis. Nature 445, 866–873.
2. Nograles, K.E., Brasington, R.D., and Bowcock, A.M. (2009).
New insights into the pathogenesis and genetics of psoriatic
arthritis. Nat. Clin. Pract. Rheumatol. 5, 83–91.
3. Capon, F., Bijlmakers, M.J., Wolf, N., Quaranta, M., Huffmeier,
U., Allen, M., Timms, K., Abkevich, V., Gutin, A., Smith, R.,
et al. (2008). Identification of ZNF313/RNF114 as a novel
psoriasis susceptibility gene. Hum. Mol. Genet. 17, 1938–
1945.
4. Cargill, M., Schrodi, S.J., Chang, M., Garcia, V.E., Brandon, R.,
Callis, K.P., Matsunami, N., Ardlie, K.G., Civello, D., Catanese,012
J.J., et al. (2007). A large-scale genetic association study
confirms IL12B and leads to the identification of IL23R as
psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290.
5. Ellinghaus, E., Ellinghaus, D., Stuart, P.E., Nair, R.P., Debrus, S.,
Raelson, J.V., Belouchi, M., Fournier, H., Reinhard, C., Ding, J.,
et al. (2010). Genome-wide association study identifies a psori-
asis susceptibility locus at TRAF3IP2. Nat. Genet. 42, 991–995.
6. Hu¨ffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Ko-
rendowych, E., Juneblad, K., Apel, M., McManus, R., Ho, P.,
et al. (2010). Common variants at TRAF3IP2 are associated
with susceptibility to psoriatic arthritis and psoriasis. Nat.
Genet. 42, 996–999.
7. Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J.,
Wise, C., Miner, A., Malloy, M.J., Pullinger, C.R., et al. (2008).
A genome-wide association study of psoriasis and psoriatic
arthritis identifies new disease loci. PLoS Genet. 4, e1000041.
8. Nair, R.P., Duffin, K.C., Helms, C., Ding, J., Stuart, P.E., Gold-
gar, D., Gudjonsson, J.E., Li, Y., Tejasvi, T., Feng, B.J., et al;
Collaborative Association Study of Psoriasis. (2009).
Genome-wide scan reveals association of psoriasis with IL-23
and NF-kappaB pathways. Nat. Genet. 41, 199–204.
9. Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E.,
Allen, M.H., Barton, A., Band, G., Bellenguez, C., Bergboer,
J.G., et al; Genetic Analysis of Psoriasis Consortium & the
Wellcome Trust Case Control Consortium 2. (2010). A
genome-wide association study identifies new psoriasis
susceptibility loci and an interaction between HLA-C and
ERAP1. Nat. Genet. 42, 985–990.
10. Stuart, P.E., Nair, R.P., Ellinghaus, E., Ding, J., Tejasvi, T., Gud-
jonsson, J.E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C., et al.
(2010). Genome-wide association analysis identifies three
psoriasis susceptibility loci. Nat. Genet. 42, 1000–1004.
11. Sun, L.D., Cheng, H., Wang, Z.X., Zhang, A.P., Wang, P.G., Xu,
J.H., Zhu, Q.X., Zhou, H.S., Ellinghaus, E., Zhang, F.R., et al.
(2010). Association analyses identify six new psoriasis suscep-
tibility loci in the Chinese population. Nat. Genet. 42, 1005–
1009.
12. Elder, J.T. (2006). PSORS1: Linking genetics and immunology.
J. Invest. Dermatol. 126, 1205–1206.
13. Nair, R.P., Stuart, P.E., Nistor, I., Hiremagalore, R., Chia, N.V.,
Jenisch, S., Weichenthal, M., Abecasis, G.R., Lim, H.W., Chris-
tophers, E., et al. (2006). Sequence and haplotype analysis
supports HLA-C as the psoriasis susceptibility 1 gene. Am. J.
Hum. Genet. 78, 827–851.
14. Vineis, P., and E Pearce, N. (2011). Genome-wide association
studies may be misinterpreted: Genes versus heritability.
Carcinogenesis 32, 1295–1298.
15. Chen, H., Poon, A., Yeung, C., Helms, C., Pons, J., Bowcock,
A.M., Kwok, P.Y., and Liao, W. (2011). A genetic risk score
combining ten psoriasis risk loci improves disease prediction.
PLoS ONE 6, e19454.
16. Bertin, J., Wang, L., Guo, Y., Jacobson, M.D., Poyet, J.L., Srini-
vasula, S.M., Merriam, S., DiStefano, P.S., and Alnemri, E.S.
(2001). CARD11 and CARD14 are novel caspase recruitment
domain (CARD)/membrane-associated guanylate kinase (MA-
GUK) family members that interact with BCL10 and activate
NF-kappa B. J. Biol. Chem. 276, 11877–11882.
17. Jordan, C.T., Cao, L., Roberson, E.D.O., Pierson, K.C., Yang, C.-
F., Joyce, C.E., Ryan, C., Duan, S., Helms, C.A., Liu, Y., et al.
(2012). PSORS2 is Due to Mutations in CARD14. Am. J.
Hum. Genet. 90, in press. Published online April 19, 2012.
10.1016/j.ajhg.2012.03.012.The Am18. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
19. Price, A.L., Kryukov, G.V., de Bakker, P.I., Purcell, S.M., Staples,
J., Wei, L.J., and Sunyaev, S.R. (2010). Pooled association tests
for rare variants in exon-resequencing studies. Am. J. Hum.
Genet. 86, 832–838.
20. R Development Core Team. (2011). R: A language and envi-
ronment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. http://www.R-project.org.
21. Tomfohrde, J., Silverman, A., Barnes, R., Fernandez-Vina,
M.A., Young, M., Lory, D., Morris, L., Wuepper, K.D., Stastny,
P., Menter, A., et al. (1994). Gene for familial psoriasis suscep-
tibility mapped to the distal end of human chromosome 17q.
Science 264, 1141–1145.
22. Vincourt, J.B., Jullien, D., Amalric, F., and Girard, J.P. (2003).
Molecular and functional characterization of SLC26A11,
a sodium-independent sulfate transporter from high endothe-
lial venules. FASEB J. 17, 890–892.
23. Reimand, J., Kull, M., Peterson, H., Hansen, J., and Vilo, J.
(2007). g:Profiler—a web-based toolset for functional profiling
of gene lists from large-scale experiments. Nucleic Acids Res.
35 (Web Server issue), W193–200.
24. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H.,
Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig,
J.T., et al; The Gene Ontology Consortium. (2000). Gene
ontology: Tool for the unification of biology. Nat. Genet. 25,
25–29.
25. Mehta, N.N., Yu, Y., Pinnelas, R., Krishnamoorthy, P., Shin,
D.B., Troxel, A.B., and Gelfand, J.M. (2011). Attributable risk
estimate of severe psoriasis on major cardiovascular events.
Am J Med. 124, 775e1–775e6.
26. Davidovici, B.B., Sattar, N., Prinz, J.C., Puig, L., Emery, P.,
Barker, J.N., van de Kerkhof, P., Sta˚hle, M., Nestle, F.O., Giro-
lomoni, G., and Krueger, J.G. (2010). Psoriasis and systemic
inflammatory diseases: Potential mechanistic links between
skin disease and co-morbid conditions. J. Invest. Dermatol.
130, 1785–1796.
27. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gera-
simova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R.
(2010). A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
28. Sua´rez-Farin˜as, M., Lowes, M.A., Zaba, L.C., and Krueger, J.G.
(2010). Evaluation of the psoriasis transcriptome across
different studies by gene set enrichment analysis (GSEA).
PLoS ONE 5, e10247.
29. Moreno-Garcı´a, M.E., Sommer, K., Shinohara, H., Bandara-
nayake, A.D., Kurosaki, T., and Rawlings, D.J. (2010). MA-
GUK-controlled ubiquitination of CARMA1 modulates
lymphocyte NF-kappaB activity. Mol. Cell. Biol. 30, 922–934.
30. Thome, M., Charton, J.E., Pelzer, C., and Hailfinger, S. (2010).
Antigen receptor signaling to NF-kappaB via CARMA1,
BCL10, and MALT1. Cold Spring Harb Perspect Biol 2,
a003004.
31. Pasparakis, M. (2009). Regulation of tissue homeostasis by NF-
kappaB signalling: Implications for inflammatory diseases.
Nat. Rev. Immunol. 9, 778–788.
32. Wullaert, A., Bonnet, M.C., and Pasparakis, M. (2011). NF-kB
in the regulation of epithelial homeostasis and inflammation.
Cell Res. 21, 146–158.erican Journal of Human Genetics 90, 796–808, May 4, 2012 807
33. Lockwood, W.W., Chari, R., Coe, B.P., Thu, K.L., Garnis, C.,
Malloff, C.A., Campbell, J., Williams, A.C., Hwang, D., Zhu,
C.Q., et al. (2010). Integrative genomic analyses identify
BRF2 as a novel lineage-specific oncogene in lung squamous
cell carcinoma. PLoS Med. 7, e1000315.
34. Hwu,W.L., Yang, C.F., Fann, C.S., Chen, C.L., Tsai, T.F., Chien,
Y.H., Chiang, S.C., Chen, C.H., Hung, S.I., Wu, J.Y., and Chen,
Y.T. (2005). Mapping of psoriasis to 17q terminus. J. Med.
Genet. 42, 152–158.
35. Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F.,
Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr,
R.H., et al. (2001). A frameshift mutation in NOD2 associ-
ated with susceptibility to Crohn’s disease. Nature 411,
603–606.
36. Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson,
J.M., Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.L., Van Gos-
sum, A., Orholm, M., et al. (1996). Mapping of a suscepti-
bility locus for Crohn’s disease on chromosome 16. Nature
379, 821–823.808 The American Journal of Human Genetics 90, 796–808, May 4, 237. van Heel, D.A., Fisher, S.A., Kirby, A., Daly, M.J., Rioux, J.D.,
and Lewis, C.M.; Genome Scan Meta-Analysis Group of the
IBD International Genetics Consortium. (2004). Inflamma-
tory bowel disease susceptibility loci defined by genome
scan meta-analysis of 1952 affected relative pairs. Hum. Mol.
Genet. 13, 763–770.
38. Fisher, S.A., Abecasis, G.R., Yashar, B.M., Zareparsi, S., Swar-
oop, A., Iyengar, S.K., Klein, B.E., Klein, R., Lee, K.E., Majewski,
J., et al. (2005). Meta-analysis of genome scans of age-related
macular degeneration. Hum. Mol. Genet. 14, 2257–2264.
39. Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P.L., Tai, A.K.,
Ripke, S., Gowrisankar, S., Vemuri, S., Montgomery, K., Yu,
Y., et al. (2011). A rare penetrant mutation in CFH confers
high risk of age-related macular degeneration. Nat. Genet.
43, 1232–1236.
40. Elder, J.T.; Cluster 17 Collaboration. (2005). Fine mapping of
the psoriasis susceptibility gene PSORS1: A reassessment of
risk associated with a putative risk haplotype lacking HLA-
Cw6. J. Invest. Dermatol. 124, 921–930.012
